AEON Biopharma, Inc. (AEON)
(Delayed Data from AMEX)
$1.02 USD
-0.03 (-2.86%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.00 -0.02 (-1.96%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for AEON Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 3 | 2 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -3 | -2 | 0 | 0 |
Non-Operating Income | -37 | 14 | 10 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -37 | 11 | 8 | 0 | NA |
Income Taxes | 0 | 1 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -37 | 10 | 8 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -37 | 10 | 8 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -3 | -2 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | 0 | -3 | -2 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -0.99 | 0.29 | 0.26 | NA | NA |
Fiscal Year end for AEON Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | -153.47 | 74.15 | 50.06 | -55.24 | 3.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | 153.47 | -74.15 | -50.06 | 55.24 | -3.53 |
Non-Operating Income | 10.64 | -43.87 | -19.71 | -16.37 | -0.32 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 164.11 | -118.02 | -71.67 | 38.88 | -3.85 |
Income Taxes | 0.00 | 0.00 | -0.50 | 0.00 | 0.09 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 164.11 | -118.02 | -71.18 | 38.88 | -3.94 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 164.11 | -118.02 | -71.18 | 38.88 | -3.94 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 38.84 | 37.27 | 37.16 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.16 | -0.28 | -0.71 | NA | NA |
Diluted Net EPS (GAAP) | 4.22 | -3.17 | -0.81 | 0.28 | -0.44 |